Search
Turoctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalThis modification to the general turoctocog alfa rFVIII structure makes N8-GP an extended half-life factor VIII molecule for factor VIII replacement therapy in patients with factor VIII deficiency, or … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104].
Cevimeline
go.drugbank.com/drugs/DB00185ApprovedCevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.
Haemagglutinin-strain A(H3N2)
go.drugbank.com/drugs/DB15475ApprovedInvestigationalMixtures: Afluria Tetra Injektionssuspension in einer FertigspritzeHaemagglutinin-strain A(H1N1)
go.drugbank.com/drugs/DB15476ApprovedInvestigationalMixtures: Afluria Tetra Injektionssuspension in einer FertigspritzePipradrol
go.drugbank.com/drugs/DB11584ApprovedWithdrawnIn addition to this, it has shown favorable effects in postpartum depressive symptoms [L2516]. … The social and in particular acute clinical harms of pipradrol derivatives have led to their control under the Misuse of Drugs Act 1971 in the UK in 2012 [T178].
Methylnaltrexone
go.drugbank.com/drugs/DB06800ApprovedInvestigationalFDA approved in 2008. … Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms.
Busulfan
go.drugbank.com/drugs/DB01008ApprovedInvestigationalAccording to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. … Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards.
Secretin human
go.drugbank.com/drugs/DB09532ApprovedInvestigationalThe hormone is produced from the enterochromaffin cells in the duodenum in response to the duodenal content with the pH less than 4.5 [L1875]. … Purified synthetic human secretin, also referred to as RG1068, is available as an intravenous injection under the market name ChiRhoStim ® in the U.S..
Idebenone
go.drugbank.com/drugs/DB09081ApprovedInvestigationalLack of improvement in cognitive function halted its production for these conditions, however it continues to be investigated for use in other conditions associated with mitochondrial damage. … LHON is a mitochondrially inherited degeneration of retinal ganglion cells, resulting in acute central vision loss.
Categories: Compounds used in a research, industrial, or household settingVanzacaftor
go.drugbank.com/drugs/DB18373ApprovedInvestigational[L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor … It is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.